A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours

Trial Profile

A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs AZD 5363 (Primary) ; Olaparib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms ComPAKT
  • Most Recent Events

    • 20 Apr 2016 Results (n=53) presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 18 Apr 2016 Results published at the 2016 American Association for Cancer Research (AACR) Annual Meeting, as per AstraZeneca media release.
    • 18 Apr 2016 Results published in AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top